Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas.

MW, Saif; H, Oettle; WL, Vervenne; JP, Thomas; G, Spitzer; C, Visseren-Grul; N, Enas; DA, Richards

doi:10.1097/ppo.0b013e3181b36264

Public

Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas.

Shared by NobleBlocks on Jul 1, 2009 • 12:00 AM UTC

Authors:

Saif MW

Oettle H

Vervenne WL

Abstract

<h4>Background</h4>LY293111 (LY) is a novel oral anticancer agent with leukotriene B4 receptor antagonist and peroxisome proliferator-activated receptor gamma agonist properties, producing promising results alone and in combination with gemcitabine in pancreatic cancer xenograft models. A phase I st...

Discussions